Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this
study is to evaluate the efficacy and adverse effect of PD-1 antibody with IMRT versus IMRT
alone in recurrent nasopharyngeal carcinoma patients.